ATC Group: A10BX Other blood glucose lowering drugs, excl. insulins

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A10BX in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A10 Drugs used in diabetes
3 A10B Blood glucose lowering drugs, excl. insulins
4 A10BX Other blood glucose lowering drugs, excl. insulins

Group A10BX contents

Code Title
A10BX01 Guar gum
A10BX02 Repaglinide
A10BX03 Nateglinide
A10BX05 Pramlintide
A10BX06 Benfluorex
A10BX08 Mitiglinide

Active ingredients in A10BX

Active Ingredient Description

Nateglinide is an amino acid (phenylalanine) derivative, which is chemically and pharmacologically distinct from other antidiabetic agents. Nateglinide is a rapid, short-acting oral insulin secretagogue. Its effect is dependent on functioning beta cells in the pancreas islets.


Pramlintide is an analog of human amylin. In human studies, pramlintide, acting as an amylin analog, slows gastric emptying, reduces the postprandial rise in plasma glucagon, and modulates satiety leading to decreased caloric intake.


Repaglinide is a short-acting oral secretagogue. Repaglinide lowers the blood glucose levels acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning β-cells in the pancreatic islets.


Tirzepatide is a long acting dual GIP and GLP-1 receptor agonist. Both receptors are present on the pancreatic α and β endocrine cells, brain, heart, vasculature, immune cells (leukocytes), gut and kidney. GIP receptors are also present on adipocytes. The activity of tirzepatide on the GIP receptor is similar to native GIP hormone. Tirzepatide improves glycaemic control by lowering fasting and postprandial glucose concentrations in patients with type 2 diabetes through several mechanisms.

Related product monographs

Title Information Source Document Type  
ENYGLID Tablet European Medicines Agency (EU) MPI, EU: SmPC
MOUNJARO Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
PRANDIN Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
REPAGLINIDE Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
STARLIX Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
ZEPBOUND Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR